Patents by Inventor Sheng-Hung Tschang

Sheng-Hung Tschang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070265200
    Abstract: The invention provides FGF-21 compounds covalently attached to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active polypeptide with an extended elimination half-life and a slower clearance when compared to that of non-PEGylated polypeptide. These PEGylated FGF-21 compounds and compositions are useful in treating diabetes, obesity, and metabolic syndrome.
    Type: Application
    Filed: March 4, 2005
    Publication date: November 15, 2007
    Applicant: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Radhakrishnan Rathnachalam, Rohn Millican, Sheng-Hung Tschang
  • Publication number: 20070253966
    Abstract: The invention provides active therapeutic peptides fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, reduced half antibody formation, and reduced effector activity, while not being immnunogenic. The fusion proteins are useful in treating human diseases as well as a variety of other conditions or disorders.
    Type: Application
    Filed: June 10, 2004
    Publication date: November 1, 2007
    Applicant: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Rohn Millican Jr, Yu Tian, Sheng-Hung Tschang, Andrew Vick
  • Publication number: 20070237768
    Abstract: The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.
    Type: Application
    Filed: May 2, 2005
    Publication date: October 11, 2007
    Applicant: ELI LILLY AND COMPANY
    Inventors: Wolfgang Glaesner, Rohn Millican, Yu Tian, Sheng-Hung Tschang
  • Publication number: 20070161087
    Abstract: The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.
    Type: Application
    Filed: January 11, 2007
    Publication date: July 12, 2007
    Inventors: Wolfgang Glaesner, Radmila Micanovic, Sheng-Hung Tschang
  • Publication number: 20060147945
    Abstract: The present invention provides nucleic acid sequences encoding novel human proteins. These novel nucleic acids are useful for constructing the claimed DNA vectors and host cells of the invention and for preparing the claimed nucleic acids, recombinant proteins and antibodies that are useful in the claimed methods and medical uses.
    Type: Application
    Filed: January 6, 2005
    Publication date: July 6, 2006
    Inventors: Brian Edmonds, Radmila Micanovic, Weijia Ou, Eric Su, Sheng-Hung Tschang, He Wang